Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis

Blood Cells, Molecules and Diseases

Volumn 23, Issue 3, 1997, Pages 380-394

  Gambacorti Passerini, Carlo ^a,b   Le Coutre, Philipp ^a   Mologni, Luca ^a   Fanelli, Mirco ^a,c   Bertazzoli, Carla ^a   Marchesi, Edoardo ^a   Di Nicola, Massimo ^a   Biondi, Andrea ^b   Corneo, Gian Marco ^b   Belotti, Daniela ^b   Pogliani, Enrico ^b   Lydon, Nicholas B ^d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ALL; Apoptosis; BCR ABL; CML; Tyrosine kinase inhibitors

Indexed keywords

IMATINIB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0031409736     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.1997.0155     Document Type: Article

References (29)

1. 1. Nature. 315:1985;758-761.
2. Konopa J B, Watanabe S M, Witte O N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 37:1984;1035-1042.
3. BCR/ABL. Science. 247:1990;824-830.
4. Calabretta B. Inhibition of proto oncogene expression by antisense oligo-deoxynucleotides: biological and therapeutic implications. Cancer Res. 51:1991;4505-4510.
5. +in vitro. Blood. 88:1996;3522-3527.
6. Cortez D, Kadlec L, Pendergast A M. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 15:1995;5531-5541.
7. Goga A, McLaughlin J, Afar D EH, Saffran D C, Witte O N. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 82:1995;981-988.
8. Carlesso L N, Frank D A, Griffin J D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 183:1996;811-820.
9. Shuai K, Halpner J, ten Hoeve J, Rao X, Sawyers C L. Constitutive activation of STAT5 by BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 13:1996;247-254.
10. Sattler M, Salgia R, Okuda K. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene. 12:1996;839-846.
11. Buchdunger E, Zimmermann J, Mett H. Inhibition of the Abl protein-kinasein vitroin vivo. Cancer Res. 56:1996;100-104.
12. Druker B J, Tamura S, Buchdunger E. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:1996;561-566.
13. 1. Int J Cell Cloning. 1:1983;105-117.
14. +. J Natl Cancer Inst. 70:1983;447-453.
15. Lozzio C B, Lozzio B B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 45:1975;321-334.
16. Kishi K. A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. Leuk Res. 9:1985;381-390.
17. Blom T, Nilsson G, Sundstroem C, Nilsson K, Hellman L. Characterization of a human basophil-like cell line. Scand J Immunol. 44:1996;54-61.
18. 1. Leuk Lymphoma. 16:1995;493-503.
19. Dermime S, Grignani F, Clerici M. The occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4.306 is associated with altered expression of the pml/RARα protein. Blood. 82:1993;1573-1577.
20. Morgan R, Smith S, Hecht B. Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of socalled malignant histiocytosis. Blood. 73:1989;2155-2164.
21. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi P P, Pelicci P G, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RARα present in acute promyelocytic leukemia cells. Blood. 81:1993;1369-1375.
22. Gambacorti-Passerini C, Radrizzani M, Erba E, Fossati G, Parmiani G. Lysis by activated lymphocytes of melanoma and small cell lung cancer cells survivingin vitro. Cancer Res. 47:1987;2547-2552.
23. Jaffe E A, Nachman R L, Becker C G, Minick C R. Culture of endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 52:1973;2745-2756.
24. +. Br J Haematol. 94:1996;716-721.
25. Biondi A, Rambaldi A, Rossi V. Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. Blood. 82:1993;2943-2947.
26. Gambacorti-Passerini C, Mologni L, Bertazzoli C, Grignani F, Marchesi E, Nielsen P E. In vitro. Blood. 88:1996;1114-1117.
27. Martin S, Reutenlingsperger C PM, McGahon A JM. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 182:1995;1545-1556.
28. Law J C, Ritke M K, Yalowich J C, Leder G H, Ferrell R E. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res. 17:1993;1045-1050.
29. Shiohara M, Akashi M, Gombart A F, Yang R, Koeffler H P. Tumor necrosis factor alpha: post transcriptional stabilization of WAF1 mRNA in p53-deficient human leukemic cells. J Cell Physiol. 166:1996;568-576.